LQDA ▲ +49.8% - Liquidia Corporation $LQDA 40 hit ! Fully resolves all six ongoing lawsuits between the companies Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH) Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics Strong financial position with $222.7 million in Q3’26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026 Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined 13-OCT-2026 06:54 PM ET